Ruxolitinib (JAKAVI®) Clinical Trials
3 recruitingDrug
Phase 21Phase 31Not Applicable1Phase 11
Showing 1–3 of 3 trials
Recruiting
Phase 1
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML)
Stephan Grupp MD PhD30 enrolled1 locationNCT07464951
Recruiting
Phase 2Phase 3
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Acute Myeloid Leukemia, RelapsedAcute Lymphoblastic Leukemia, High RiskAcute Myeloid Leukemia, High Risk+1 more
Federal Research Institute of Pediatric Hematology, Oncology and Immunology64 enrolled1 locationNCT07366801
Recruiting
Not Applicable
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
Graft vs Host Disease
First Affiliated Hospital of Zhejiang University122 enrolled1 locationNCT07184853